GLP-1 Receptor Agonists Reduce Cardiovascular Risk Among Atopic Dermatitis Patients, Suggests Study

The study, published in Dermatitis by Abigail Katz and colleagues from the Icahn School of Medicine at Mount Sinai, explored whether GLP-1 receptor agonists (GLP-1RAs) could reduce the risk of major adverse cardiovascular events (MACE) in patients with atopic dermatitis (AD). AD, a chronic inflammatory skin disorder, has increasingly been linked to higher cardiovascular risk, prompting interest in therapies that may address both dermatologic and metabolic pathways.

For this purpose, the researchers conducted a large retrospective cohort study using data from the TriNetX Research Network. The analysis included patients aged 12 years and older diagnosed with AD between April 2005 and December 2020. Among more than 547,000 individuals with AD, approximately 24,900 had been treated with GLP-1RAs. These patients were matched in a 1:1 ratio with those not receiving GLP-1RAs, ensuring comparable baseline characteristics such as demographics and cardiovascular risk factors.

The primary outcome assessed was the incidence of major cardiovascular events, including cerebrovascular disease, heart failure, atherosclerosis, ischemic heart disease, and the need for percutaneous coronary intervention. Outcomes were evaluated over extended follow-up periods of 5, 10, and 20 years.   

The study adds to the growing body of evidence supporting the systemic benefits of GLP-1RAs beyond glycemic control. Their anti-inflammatory and metabolic effects may be particularly relevant in conditions like atopic dermatitis, where chronic inflammation may contribute to long-term cardiovascular complications.

Although the observational design limits the ability to establish causality, the large sample size and robust matching methodology strengthen the findings. The authors noted that further prospective studies are needed to confirm these associations and better understand the underlying mechanisms.

Overall, the results suggest that GLP-1 receptor agonists may offer dual benefits for patients with atopic dermatitis by addressing both dermatologic symptoms and long-term cardiovascular risk. This could have important implications for clinical decision-making, particularly in patients with coexisting metabolic or cardiovascular risk factors.

Reference:

Katz, A., Nong, Y., Ma, E. J., Roberts, A. M., Chou, P. P., Jeong, C. Y., Yan, M. J., Johnsen, N., & Armstrong, A. W. Effects of GLP-1 Receptor Agonists on Major Cardiovascular Events Among Patients with Atopic Dermatitis: A Population-Based Study. Dermatitis®. https://doi.org/10.1177_17103568251410211